Taking into account the aforementioned publications, it should not be forgotten that omeprazole will reduce
secretions at the respiratory level. A positive effect on respiratory secretions during acute viral respiratory diseases
which can become negative (by modifying the pH, the ciliary mobility and the volume of secretions) during
prolonged use, thus promoting the risk of bacterial pneumonia (29).

The advantages and disadvantages may vary depending on the user phenotype of omeprazole with regard to
cytochrome P 450 (30).

Best regards

Johannes Hambura

1. Long J, Wright E, Molesti E, Temperton N, Barclay W. Antiviral therapies against Ebola and other emerging
Viral diseases using existing medicines that block virus entry. F1000Res. 2015;4:30. Published 2015 Jan 29.
doi: 10.12688/f1 000research.6085.2

2. Dowall SD, Bewley K, Watson RJ, et al. Antiviral Screening of Multiple Compounds against Ebola Virus.
Viruses. 2016;8(11):277. Published 2016 Oct 27. doi:10.3390/v8 110277

3. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J
Neurogastroenterol Motil. 2013;19(1):25—-35. doi:10.5056/jnm.2013.19.1.25

4. Spugnini EP, Citro G, Fais S. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer
strategy. J Exp Clin Cancer Res. 2010;29(1):44. Published 2010 May 8. doi:10.1186/1756-9966-29-44

5. Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, Kubo H, Nishimura H, Sasaki H. The proton pump
inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol.
2005;14:201-210. doi: 10.1016/j.ejphar.2004. 12.042.

6. | Gasparini R, Lai PL, Casabona F, et al. Do the omeprazole family compounds exert a protective effect against
influenza-like illness?. BMC Infect Dis. 2014;14:297. Published 2014 Jun 2. doi:10.1186/1471-2334-14-297

7. Moormann AEBDP, Flynn DL, Hui LI, Villamil CI, Inventor method of using (H+/K+)ATPase inhibitors as
antiviral agents. United States1999 Jun. 14, 2005S.

8. Kikuchi S, Naoki Y, Tajiri T, Watanabe N. Proton pump inhibitors for chronic obstructive pulmonary disease.
Cochrane Database Syst Rev. 2018;2018(8):CD013113. Published 2018 Aug 30. doi:10.1002/14651858.CD013113

9. Modyanov N, Pestov N, Adams G, Crambert G, Tillekeratne M, Zhao H, Korneenko T, Shakhparonov M,
Geering K. Nongastric H,K-ATPase: structure and functional properties. Ann N Y Acad Sci. 2003 Apr; 986():183-7.

10. Matsui MS, Petris MJ, Niki Y, Karaman-Jurukovska N, Muizzuddin N, Ichihashi M, Yarosh DB. Omeprazole,
a gastric proton pump inhibitor, inhibits melanogenesis by blocking ATP7A trafficking. J Invest Dermatol. 2015
Mar; 135(3):834-841.

11. De Milito A, Canese R, Marino ML, Borghi M, Tero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M,
Mina PD, Santinami M, Rodolfo M, Podo F, Rivoltini L, Fais S. pH-dependent antitumor activity of proton pump
inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2009.

12. Lee YY, Jeon HK, Hong JE, et al. Proton pump inhibitors enhance the effects of cytotoxic agents in
chemoresistant epithelial ovarian carcinoma. Oncotarget. 2015;6(33):35040—35050. doi:10.18632/oncotarget.5319

13. Larsson H, Mattson H, Sundell G, Carlsson E. Animal pharmacodynamics of omeprazole. A survey of its

NIH-001967
